Compare FTHY & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTHY | SENS |
|---|---|---|
| Founded | 2020 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Industrial Machinery/Components |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.5M | 397.1M |
| IPO Year | 2020 | 2014 |
| Metric | FTHY | SENS |
|---|---|---|
| Price | $13.01 | $9.32 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $13.67 |
| AVG Volume (30 Days) | 113.0K | ★ 554.7K |
| Earning Date | 01-01-0001 | 11-09-2026 |
| Dividend Yield | ★ 10.93% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,389,000.00 |
| Revenue This Year | N/A | $82.21 |
| Revenue Next Year | N/A | $55.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 19.85 |
| 52 Week Low | $12.49 | $4.79 |
| 52 Week High | $14.34 | $10.64 |
| Indicator | FTHY | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 58.29 | 57.57 |
| Support Level | $12.93 | $8.45 |
| Resistance Level | $13.11 | $10.07 |
| Average True Range (ATR) | 0.18 | 0.53 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 90.00 | 98.13 |
FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND is a diversified, closed-end management investment company. The investment objective of the fund is to provide current income. The fund invests a majority of its managed assets in high-yield debt securities of any maturity that are rated below investment grade at the time of purchase or unrated securities. Its investment portfolio comprises corporate bonds and notes, senior floating-rate loan interests, foreign corporate bonds and notes, money market funds, and other instruments across various industries.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.